Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Lays Off 62 Employees

NEW YORK, June 30 (GenomeWeb News) - Exelixis announced today that it has eliminated 62 jobs, or approximately 11 percent of the company's workforce.


According to an official company statement, most of the layoffs will be from Exelixis' research and discovery organizations as the company attempts to consolidate it resources to generate new investigational new drug applications and advance them through clinical development.


The company said it expects the restructuring to result in at least $5 million in savings in 2004, excluding the estimated $2 million loss due to severance benefits and other restructuring costs anticipated in Q2 of this year.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.